- Home
- GPMT vs NOTV Comparison
GPMT vs NOTV Comparison
Compare GPMT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPMT
- NOTV
- Stock Information
- Founded
- GPMT 2015
- NOTV 1974
- Country
- GPMT United States
- NOTV United States
- Employees
- GPMT N/A
- NOTV N/A
- Industry
- GPMT Real Estate Investment Trusts
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- GPMT Real Estate
- NOTV Health Care
- Exchange
- GPMT Nasdaq
- NOTV Nasdaq
- Market Cap
- GPMT N/A
- NOTV 137.5M
- IPO Year
- GPMT 2017
- NOTV 1997
- Fundamental
- Price
- GPMT $2.51
- NOTV $2.41
- Analyst Decision
- GPMT Buy
- NOTV Strong Buy
- Analyst Count
- GPMT 3
- NOTV 3
- Target Price
- GPMT $3.38
- NOTV $5.92
- AVG Volume (30 Days)
- GPMT 288.8K
- NOTV 545.2K
- Earning Date
- GPMT 05-06-2025
- NOTV 05-09-2025
- Dividend Yield
- GPMT 7.97%
- NOTV N/A
- EPS Growth
- GPMT N/A
- NOTV N/A
- EPS
- GPMT N/A
- NOTV N/A
- Revenue
- GPMT N/A
- NOTV $475,114,000.00
- Revenue This Year
- GPMT N/A
- NOTV $6.37
- Revenue Next Year
- GPMT $34.66
- NOTV $5.74
- P/E Ratio
- GPMT N/A
- NOTV N/A
- Revenue Growth
- GPMT N/A
- NOTV N/A
- 52 Week Low
- GPMT $2.46
- NOTV $1.23
- 52 Week High
- GPMT $4.60
- NOTV $10.19
- Technical
- Relative Strength Index (RSI)
- GPMT 29.21
- NOTV 40.48
- Support Level
- GPMT $2.67
- NOTV $1.98
- Resistance Level
- GPMT $2.77
- NOTV $3.35
- Average True Range (ATR)
- GPMT 0.09
- NOTV 0.31
- MACD
- GPMT -0.03
- NOTV -0.02
- Stochastic Oscillator
- GPMT 2.41
- NOTV 31.39
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.